Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177242 | 1.00 | TSHR (0.41) | TSHRMAPK10SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL4177246 | 1.00 | TSHR (0.41) | TSHRMAPK10SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL4172212 | 0.86 | ALDH1A1 (0.51) | SMN1; SMN2LMNAMAPTEGFRALDH1A1 | |
| SCHEMBL4172211 | 0.86 | ALDH1A1 (0.51) | SMN1; SMN2LMNAMAPTEGFRALDH1A1 | |
| SCHEMBL4172208 | 0.86 | ALDH1A1 (0.51) | SMN1; SMN2LMNAMAPTEGFRALDH1A1 | |
| SCHEMBL4176422 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAMAPTEGFRALDH1A1 | |
| SCHEMBL4176418 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAMAPTEGFRALDH1A1 | |
| SCHEMBL4176425 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAMAPTEGFRALDH1A1 | |
| SCHEMBL4178970 | 0.83 | HPGD (0.45) | TSHRCYP1A2MAPTCA2CA1 | |
| SCHEMBL4178964 | 0.83 | HPGD (0.45) | TSHRCYP1A2MAPTCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-07-30 | — | — | US | claimed |
| EP-2046322-A2 | ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2009-04-15 | — | — | EP | claimed |
| WO-2008016682-A2 | ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-02-07 | — | — | WO | claimed |
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | ARSA, STS, SULT2A1 | TSHR 1154/4885MAPK10 2823/4885SMN1; SMN2 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.